SCYX
Scynexis Inc
NASDAQ: SCYX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$4.81
-0.52% today
Updated 2026-08-12
Market cap
$299.50M
P/E ratio
—
P/S ratio
14.72x
EPS (TTM)
$-3.99
Dividend yield
—
52W range
$4 – $10
Volume
0.2M
WallStSmart proprietary scores
35
out of 100
Grade: D
Sell
Investment rating
8.0
Growth
A7.0
Quality
B+2.0
Profitability
F5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
-5.5
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →218 stocks currently score above 75
Price targets
Analyst target
$33.55
+597.51%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 1,809.00% QoQ
+ Debt/equity 0.05x — low leverage
Risks
- Altman Z -5.48 — distress zone
- Thin margins at -120.50%
- Negative free cash flow $-8.10M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $5.09M | $140.14M | $3.75M | $20.60M | $20.34M |
| Net income | $-62.81M | $67.04M | $-21.29M | $-8.61M | $-21.30M |
| EPS | — | — | — | — | $-3.99 |
| Free cash flow | $-79.89M | $0.00 | $-24.01M | $-5.28M | $-8.10M |
| Profit margin | -1,233.73% | 47.84% | -568.29% | -41.79% | -120.50% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-26 | TINMOUTH, BRIAN PHILIPPE | Buy | 2,875 | — |
| 2026-06-26 | TINMOUTH, BRIAN PHILIPPE | Buy | 2,875 | — |
| 2026-06-26 | MACDONALD, GUY | Buy | 2,875 | — |
Peer comparison
Smart narrative
Scynexis Inc trades at $4.81. Our Smart Value Score of 35/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -5.48, it sits in the distress. TTM revenue stands at $20.34M. with profit margins at -120.50%.
Frequently asked questions
What is Scynexis Inc's stock price?
Scynexis Inc (SCYX) trades at $4.81, on a P/S of 14.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Scynexis Inc overvalued?
Scynexis Inc carries a Smart Value Score of 35/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Scynexis Inc (SCYX)?
The 12-month analyst consensus target is $33.55, about 597.5% above the current $4.81. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Scynexis Inc's revenue?
Scynexis Inc's trailing twelve-month revenue is $20.34M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Scynexis Inc's Altman Z-Score is -5.48, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio14.72x
ROE-53.40%
Beta1.10
50D MA$4.49
200D MA$5.76
Shares out0.08B
Float0.01B
Short ratio—
Avg volume0.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—